{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:54:38Z","timestamp":1790891678300,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ucl.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:52:30Z","timestamp":1785455550000},"page":"517-526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Jackson","family":"Eber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Matulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2026.06.001_bib1","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","author":"Filho","year":"2025","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.ucl.2026.06.001_bib3","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2026.06.001_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1546160","article-title":"Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer","volume":"15","author":"Attanasio","year":"2025","journal-title":"Front Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.06.001_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.2022.40.6_suppl.575","article-title":"Five-year survival comparison of different treatment modalities for muscle invasive urothelial carcinoma, squamous cell carcinoma and adenocarcinoma of the bladder: an analysis of the National Cancer Database","volume":"40","author":"Rivera","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.12.018","article-title":"Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice","volume":"44","author":"Squires","year":"2026","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102466","article-title":"Treatment patterns, disease recurrence, and overall survival in patients with muscle-invasive bladder cancer after radical cystectomy: a population-level claims-based analysis","volume":"24","author":"Squires","year":"2026","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.001_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.001_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bju.14872","article-title":"The natural history of untreated muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2020","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.001_bib12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/JU.0000000000000350","article-title":"A nationwide, population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014","volume":"202","author":"Westergren","year":"2019","journal-title":"J Urol"},{"issue":"19","key":"10.1016\/j.ucl.2026.06.001_bib13","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.3390\/cancers16193330","article-title":"Muscle-invasive bladder cancer in non-curative patients: a study on survival and palliative care needs","volume":"16","author":"Guerrero-Ramos","year":"2024","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ucl.2026.06.001_bib14","doi-asserted-by":"crossref","first-page":"246.e7","DOI":"10.1016\/j.urolonc.2024.03.009","article-title":"Natural history and health care burden of non-curative treatment for muscle-invasive bladder cancer","volume":"42","author":"Herzberg","year":"2024","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.06.001_bib15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/jnci\/djaa216","article-title":"Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges","volume":"113","author":"Krishnamoorthy","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.001_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ucl.2026.06.001_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005036","article-title":"Neoadjuvant immunotherapy of locoregionally advanced solid tumors","volume":"10","author":"Tarhini","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"Pt 2","key":"10.1016\/j.ucl.2026.06.001_bib18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.semcancer.2022.05.015","article-title":"Neoadjuvant immunotherapy in gastrointestinal cancers - the new standard of care?","volume":"86","author":"Petricevic","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"20","key":"10.1016\/j.ucl.2026.06.001_bib19","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2001.19.20.4005","article-title":"Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC","volume":"19","author":"Millikan","year":"2001","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.001_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ucl.2026.06.001_bib21","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/cncr.24466","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ucl.2026.06.001_bib22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.001_bib23","first-page":"CD005246","article-title":"Neoadjuvant chemotherapy for invasive bladder cancer","volume":"2004","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"9373","key":"10.1016\/j.ucl.2026.06.001_bib24","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.001_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.001_bib26","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.001_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2026.06.001_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.urology.2024.04.034","article-title":"Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: a systematic review and pooled meta-analysis to determine the preferred regimen","volume":"188","author":"Eule","year":"2024","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.001_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ucl.2026.06.001_bib30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jmg.2010.076992","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"van der Post","year":"2010","journal-title":"J Med Genet"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.001_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"17","key":"10.1016\/j.ucl.2026.06.001_bib32","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"10.1016\/j.ucl.2026.06.001_bib33","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median Follow-Up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.001_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.06.001_bib36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2026.06.001_bib37","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"10.1016\/j.ucl.2026.06.001_bib38","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"0","key":"10.1016\/j.ucl.2026.06.001_bib39","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"0","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.001_bib40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.ucl.2026.06.001_bib41","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.24.00576","article-title":"First results of NURE-Combo: a phase II study of neoadjuvant nivolumab and nab-Paclitaxel, followed by postsurgical adjuvant nivolumab, for muscle-invasive bladder cancer","volume":"42","author":"Mercinelli","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.001_bib42","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S1470-2045(25)00358-4","volume":"26","author":"Necchi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ucl.2026.06.001_bib43","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.001_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ucl.2026.06.001_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial","author":"Dyrskj\u00f8t","year":"2026","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.06.001_bib46","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:59:16Z","timestamp":1790888356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0094014326000546"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}